Difference between revisions of "Team:Evry/Project/SurfaceDisplay"

Line 42: Line 42:
 
<p class="text-justify">To establish a proof of concept, our system was tested in vivo on C57BL/6 mice injected with the melanoma cell line B16-OVA expressing the ovalbumin antigen. We also tested the system in vitro on hybridoma B3Z T-cells specific for SIINFEKL. The tumor antigen cloned in our vector was OVA1 corresponding to the sequence QLESIINFEKLTEW, class I (Kb)-restricted peptide epitope of ovalbumin (OVA) plus 3 amino acids around the epitope to allow better digestion by the proteasome. It is presented by the class I MHC molecule H-2Kb (29).</p>
 
<p class="text-justify">To establish a proof of concept, our system was tested in vivo on C57BL/6 mice injected with the melanoma cell line B16-OVA expressing the ovalbumin antigen. We also tested the system in vitro on hybridoma B3Z T-cells specific for SIINFEKL. The tumor antigen cloned in our vector was OVA1 corresponding to the sequence QLESIINFEKLTEW, class I (Kb)-restricted peptide epitope of ovalbumin (OVA) plus 3 amino acids around the epitope to allow better digestion by the proteasome. It is presented by the class I MHC molecule H-2Kb (29).</p>
  
<img src="https://static.igem.org/mediawiki/2015/a/ab/Sch%C3%A9ma.jpg"  usemap="#imgmap2015916171923" id='image-map-py' width="1024"/>
+
<img src="https://static.igem.org/mediawiki/2015/a/ab/Sch%C3%A9ma.jpg"  usemap="#imgmap2015916171923" id='image-map-py' width="5000"/>
  
  

Revision as of 22:02, 18 September 2015

Scroll to top To top